#India – Ranbaxy Lab Lted agrees selling adulterated drugs, fined $500 million penalty

Associated PressWASHINGTON (AP) – A subsidiary of India’s largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S.

Federal prosecutors say the guilty plea by Ranbaxy USA Inc. represents the largest financial penalty against a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs.

The deal, announced Monday, concludes a years-long federal investigation into Ranbaxy’s manufacturing deficiencies. The Food and Drug Administration in 2008 barred from Ranbaxy from importing more than 30 different drugs made at factories in India and, two years ago, struck a deal that required the company to ensure that data on its products is accurate, undergo extra oversight and review from a third-party and improve its drug making procedures.

The subsidiary of Ranbaxy Laboratories Limited pleaded guilty to federal criminal charges and the company separately agreed to resolve civil claims with all 50 states and the District of Columbia. The company had earlier set aside $500 million to cover potential criminal and civil liability stemming from the Justice Department investigation.

It admitted as part of the deal that it sold adulterated batches of drugs – including an antibiotic and generic versions of medications used to treat severe acne, epilepsy and nerve pain – that were developed at two manufacturing sites in India. It’s not known whether the problems with the drugs led to any health issues. The problems were largely revealed by a whistleblower in a federal lawsuit filed in Maryland in 2007. The government’s allegations against the company make no claims that the drugs, whose strength, purity or quality differed from the specifications, harmed anyone.

The company admitted to a wide range of deficiencies, including improperly storing drug samples that awaiting testing, continuing to sell a medication in the U.S. even after it had failed purity tests and delaying a voluntary recall of medication that it knew would not maintain its expected its expected shelf life.

Ranbaxy also admitted making false statements to the FDA in 2006 and 2007 annual reports about dates of tests that are designed to detect drug impurities and determine appropriate storage conditions. In some cases, the tests were done weeks or months after the company said they’d been performed. Or the tests were done on the same day – or within days of each other – instead of months apart, the prescribed interval.

The company said in a written statement that it had fully cooperated with the investigation, which it said involved actions from several years ago, and expects “future growth in the U.S. and around the world with a robust pipeline of important products.”

“While we are disappointed by the conduct of the past that led to this investigation, we strongly believe that settling this matter now is in the best interest of all of Ranbaxy’s stakeholders; the conclusion of the DOJ investigation does not materially impact our current financial situation or performance,” Ranbaxy CEO and managing director Arun Sawhney said in a statement.

The company had faced scrutiny in recent years. Apart from the federal investigation, Ranbaxy Pharmaceuticals Inc. – also a subsidiary of Ranbaxy Laboratories Limited – halted in November of generic cholesterol drug Lipitor while it investigated how tiny glass particles got into dozens of recalled batches. The FDA determined at the time that the risk to patients was very low.

The case comes as federal regulators and prosecutors focus attention on the quality of ingredients of generics and other drugs manufactured overseas, said Allan Coukell, an expert on drug safety at The Pew Charitable Trusts. He said the 2008 deaths linked to tainted batches of the blood-thinner heparin that were imported from China served as a “wake up call” about just how much of the nation’s drug supply comes from overseas.

“Over the last few years, the FDA and others have been increasingly focused on the risks associated with global drug manufacturing. The agency now has new authority and new resources which should result in an increased scrutiny on the highest-risk facilities,” he said.

The company agreed as part of Monday’s deal to a fine and forfeiture of $150 million as well as an additional $350 million penalty to settle civil claims that it submitted false statements to Medicaid, Medicare and other government health care programs. Nearly $49 million of that penalty will go to a former Ranbaxy executive, Dinesh Thakur, who acted as a whistleblower by filing a federal lawsuit accusing the company of knowingly falsifying drug data, prosecutors said.

Thakur said in a statement that the company had been notified of the problems, and “when they failed to correct the problems, it left me with no choice but to alert healthcare authorities.”

“He was the source, the original source, of the information to the government that ultimately led to the government’s earlier actions,” said Andrew Beato, one of Thakur’s lawyers.


Dinesh Thakur created a space for hindi theatre in Mumbai


Dinesh Thakur

Sep 21,  Mumbai, Mid day

Veteran theatre and cinema stalwart Dinesh Thakur passed away after a prolonged illness, leaving behind a huge void in Hindi cinema and theatre

As recently as late August, Ank Productions, which Dinesh Thakur and wife Preeta had staged Ravindranjali, which brought alive the magic of Gurudev Rabindranath Tagore’s songs on stage with an artistic expression of some of the legend’s most beautiful creations, through music, drama and dance. Ank was close to the theatre and cinema veteran’s heart till the end. His oldest and still popular theatre production is Jis Lahore Nahi Dekhya.

Veteran theatre actor-director Dinesh Thakur, known for his character roles in Hindi films of the 70s, passed away here today after prolonged illness.

Dinesh Thakur was suffering from kidney ailments and died at a suburban Andheri hospital, family sources said. He was 65 and is survived by actor-wife Prita Mathur. Dinesh Thakur has several acclaimed films like Mere Apne, Rajanigandha and Ghar to his credit. He headed a theatre group called ANK Productions for the last three decades. His oldest and still popular theatre production is Jis Lahore Nahi Dekhya.

Dinesh Thakur had showcased his play Rang Bajrang at the Prithvi and Tata theatres in April last year. He was a noted Indian theatre director, actor in theatre, television and Hindi films, where most notably he appeared as one of the leads in Rajnigandha (1974) directed by Basu Chatterjee, which won both Filmfare Best Movie Award and the Filmfare Critics Award for Best Movie. He appeared in character roles in Hindi films and also was a screenwriter and story writer.

He is known for writing the story and screenplay of Ghar (1978), which won him the 1979 Filmfare Best Story Award.

Dinesh Thakur’s last rites will be conducted today at the Oshiwara crematorium around 4.30 pm.

Four contemporaries from cinema and theatre reflect on this immeasurable loss:

Rahul daCunha: Dinesh was a true doyen of Hindi theatre. A pioneer in his field, he went ahead and creditably made a living from it when no one else dared to.

Amol PalekarThough we worked with each other in Rajnigandha, we shared a bond before that. Both of us played the same character in the play Adhe Adhure, in two different productions, his was directed by Om Shivpuri, whereas I acted in the one directed by Satyadev Dubey. Another funny thing about the movie was that he being from Delhi, all his scenes were shot in Mumbai, and all my scenes were shot in Delhi. We all eventually had a reunion at the after party, at producer Suresh Jindal’s residence. Since the movie, we have shared a close friendship. Even when I learnt of his illness, I rushed to Mumbai but he was already in ICU.

Salim Arif: Dinesh Thakur was like family to me. My wife Lubna has also worked with him. I designed the costumes for his famous play, Jis Lahore Nahi Dekhya. That was nearly 10 to 12 years ago. He was very fond of all of us. With his demise, theatre has lost a very important soldier. He was committed to theatre for three decades. Though he initially did a few films, he made a conscious choice to be in theatre and devote his life to theatre, which I believe is remarkable. Many young and talented actors have worked with him. What many people don’t know about him is that he was also a very good teacher. He trained several artists too. Dineshji has been one of the people responsible for creating a space for Hindi theatre in a city like Mumbai.

Shabana Azmi: It’s a big loss to the theatre world. Ank (Thakur’s theatre group) has established themselves as serious players on the theatre scene. He was ailing for sometime but fought back and would come to all important theatre events in his immaculately starched kurtas. We mourn his loss and condolences to the family.

— Compiled by Surekha S and Dhara Vora , Mid day



Kractivism-Gonaimate Videos

Protest to Arrest

Faking Democracy- Free Irom Sharmila Now

Faking Democracy- Repression Anti- Nuke activists


Kamayaninumerouno – Youtube Channel


Enter your email address to follow this blog and receive notifications of new posts by email.

Join 6,227 other followers

Top Rated

Blog Stats

  • 1,848,422 hits


October 2021
%d bloggers like this: